ArticleCancer immunology, immunotherapy : CII2023

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.

Colt A Egelston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.